Kepler-86

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts

Monday, September 13, 2021 - 2:48pm

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company

Key Points: 
  • Rather than speculate on each drug's market potential, HPM reached out to Mr. David Luci, CEO of Acurx, allowing him to respond to investor questions.
  • Acurx is outside that mold because we have a new class of antibiotics treating life-threatening infections with two in the class.
  • Our scientific team has indicated publicly that these data portend future success in Phase 2b and Phase 3.
  • Q: The Phase 2b trial can be transformative to Acurx, especially if data proves superior to standard of care Vancomycin in the imminent head-to-head match-up.

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts

Monday, September 13, 2021 - 1:03pm

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company

Key Points: 
  • Rather than speculate on each drug's market potential, HPM reached out to Mr. David Luci, CEO of Acurx, allowing him to respond to investor questions.
  • Acurx is outside that mold because we have a new class of antibiotics treating life-threatening infections with two in the class.
  • Our scientific team has indicated publicly that these data portend future success in Phase 2b and Phase 3.
  • Q: The Phase 2b trial can be transformative to Acurx, especially if data proves superior to standard of care Vancomycin in the imminent head-to-head match-up.

Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria

Thursday, August 5, 2021 - 9:01pm

Nedosiran achieved the primary endpoint in the PHYOX2 trial, demonstrating a statistically significant reduction from baseline in urinary oxalate (Uox) excretion compared to placebo (p

Key Points: 
  • Nedosiran achieved the primary endpoint in the PHYOX2 trial, demonstrating a statistically significant reduction from baseline in urinary oxalate (Uox) excretion compared to placebo (p
  • Uox reductions were significant in participants with PH1 while participants with PH2 (5 nedosiran and 1 placebo) showed inconsistent results in this trial.
  • We expect the results from the PHYOX2 trial to support marketing authorization applications in the U.S. and other major markets.
  • PHYOX2 is part of the broader PHYOX clinical trial program designed to evaluate nedosiran in participants with PH1, PH2 and PH3.

Dicerna™ Presents Additional Data from PHYOX™1 Study of DCR-PHXC in Patients with Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)

Friday, June 21, 2019 - 12:30pm

Investigators reported additional results evaluating DCR-PHXC in patients with primary hyperoxaluria type 1 (PH1) and type 2 (PH2), building on previously disclosed data showing substantial reductions in 24-hour urinary oxalate levels following a single-dose of DCR-PHXC.

Key Points: 
  • Investigators reported additional results evaluating DCR-PHXC in patients with primary hyperoxaluria type 1 (PH1) and type 2 (PH2), building on previously disclosed data showing substantial reductions in 24-hour urinary oxalate levels following a single-dose of DCR-PHXC.
  • The results will be presented at the Oxalosis & Hyperoxaluria Foundation (OHF) International Hyperoxaluria Workshop in Boston on June 22.
  • The latest data from PHYOX1 provide more information on the effects of DCR-PHXC in individuals with PH1 as well as individuals with PH2.
  • Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort.

Dicerna™ Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)

Friday, March 29, 2019 - 10:30am

The data showed post-dose reductions in 24-hour urinary oxalate levels in adult and adolescent study participants with primary hyperoxaluria type 1 (PH1) and type 2 (PH2).

Key Points: 
  • The data showed post-dose reductions in 24-hour urinary oxalate levels in adult and adolescent study participants with primary hyperoxaluria type 1 (PH1) and type 2 (PH2).
  • The data were presented in a poster on March 28 at the German Society of Pediatric Nephrology 50th Annual Meeting in Cologne, Germany.
  • Studies have shown that people who are completely deficient in LDHA show no liver dysfunction and can lead normal lives.
  • Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.